CYD0281, a Bcl-2 BH4 domain antagonist, inhibits tumor angiogenesis and breast cancer tumor growth
Abstract Background B-cell lymphoma 2 (Bcl-2) family proteins are key regulators of apoptosis, which possess four conserved Bcl-2 homologies (BH) domains. Among the BH domains, the BH3 domain is considered as a potent ‘death domain’ while the BH4 domain is required for anti-apoptotic activity. Bcl-2...
Main Authors: | Yihua Lin, Yiling Zhao, Minggui Chen, Zishuo Li, Qiao Liu, Jian Chen, Yi Ding, Chunyong Ding, Ye Ding, Cuiling Qi, Lingyun Zheng, Jiangchao Li, Rongxin Zhang, Jia Zhou, Lijing Wang, Qian-Qian Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-05-01
|
Series: | BMC Cancer |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12885-023-10974-4 |
Similar Items
-
Structural insights into apoptotic regulation of human Bfk as a novel Bcl-2 family member
by: Dong Man Jang, et al.
Published: (2022-01-01) -
STRUCTURAL BIOLOGY OF THE INTRINSIC CELL DEATH PATHWAY: WHAT DO WE KNOW AND WHAT IS MISSING?
by: Walter Douglas Fairlie, et al.
Published: (2012-04-01) -
Apoptotic Blocks in Primary Non-Hodgkin B Cell Lymphomas Identified by BH3 Profiling
by: Ryan N. Rys, et al.
Published: (2021-02-01) -
BH3 Mimetics for the Treatment of Prostate Cancer
by: Philipp Wolf
Published: (2017-08-01) -
Co-Operativity between MYC and BCL-2 Pro-Survival Proteins in Cancer
by: Walter Douglas Fairlie, et al.
Published: (2021-03-01)